What This Instrument Does
The National Health (Growth Hormone Program) Special Arrangement Amendment Instrument (July Update) Instrument 2026 is a technical update to the National Health (Growth Hormone Program) Special Arrangement, which governs how growth hormone treatments are supplied and funded under the National Health Act 1953.
The instrument amends the existing Growth Hormone Program arrangement, known as PB 112 of 2025. It was in force from 30 June 2026 to 12 October 2026, when it was repealed.
What Is Not Specified
The source text does not specify the exact clinical, administrative, or funding changes made under this amendment. It also does not specify who administers the program day to day, or why the instrument was repealed.
Administration
This instrument is administered by the Department of Health, Disability and Ageing. It is relevant mainly to health providers and pharmacies involved in supplying growth hormone treatments rather than general small businesses.
Key Actions
- Health and pharmacy businesses involved in supplying growth hormone treatments can check the current version of the National Health (Growth Hormone Program) Special Arrangement 2025 on the Federal Register of Legislation at legislation.gov.au to confirm which rules now apply, since this amendment has already been repealed.
- The 'Set up an alert' or 'Save this title to My Account' features on the Federal Register of Legislation page for this instrument are available for those who want to be notified of further changes.
This is a plain-English summary for information only, not legal or compliance advice. Always check the official source or consult a qualified professional.